Tyra Biosciences (NASDAQ:TYRA) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock.

TYRA has been the subject of several other research reports. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. UBS Group assumed coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $30.50.

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $12.59 on Tuesday. The company’s 50 day simple moving average is $14.69 and its 200-day simple moving average is $18.36. The company has a market capitalization of $637.05 million, a price-to-earnings ratio of -7.82 and a beta of 1.05. Tyra Biosciences has a 1 year low of $11.89 and a 1 year high of $29.60.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the transaction, the director now owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. This trade represents a 0.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 21,998 shares of company stock worth $344,818 in the last three months. Company insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $31,000. US Bancorp DE purchased a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $50,000. BNP Paribas Financial Markets purchased a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $60,000. Aquatic Capital Management LLC purchased a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $64,000. Finally, Wells Fargo & Company MN raised its stake in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock valued at $132,000 after purchasing an additional 3,236 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.